Michael Hencke
Public Communications Contact chez BIOGEN INC.
Profil
Michael Hencke is the founder of Semprus BioSciences Corp.
He is currently working as the Executive Director-Investor Relations at Biogen, Inc. Mr. Hencke has an undergraduate degree from Massachusetts Institute of Technology and an MBA from Harvard Business School.
Postes actifs de Michael Hencke
Sociétés | Poste | Début |
---|---|---|
BIOGEN INC. | Public Communications Contact | 14/03/2023 |
Anciens postes connus de Michael Hencke
Sociétés | Poste | Fin |
---|---|---|
Semprus BioSciences Corp.
Semprus BioSciences Corp. Pharmaceuticals: GenericHealth Technology Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices. | Founder | - |
Formation de Michael Hencke
Massachusetts Institute of Technology | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BIOGEN INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Semprus BioSciences Corp.
Semprus BioSciences Corp. Pharmaceuticals: GenericHealth Technology Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices. | Health Technology |